Clinical Trials Logo

Clinical Trial Summary

The majority of endometrial cancer patients with disease spread beyond the uterus will progress within 1 year. Platinum-based chemotherapy was used as the first-line treatment in metastatic or advanced endometrial cancer. There is no standard protocol for the second-line option when tumors persist or recur. In vitro and in vivo studies showed Crizotinib, an approved drug for the treatment of ALK-positive non-small cell lung cancer, demonstrated activities in endometrial cancer with c-MET kinase and Sema domain mutations. As a consequence, a phase 2 clinical trial to investigate the efficacy of Crizotinib in endometrial cancer patients with MET mutation is initiated.


Clinical Trial Description

In this phase 2 study, the target population is patients with recurrent or persistent metastatic endometrial cancer. The mutation status of c-MET gene will be tested and only patients with c-MET mutation will be enrolled. After enrollment, Crizotinib 250 mg bid will be used orally. CT scan or MRI will be used to determine the response. Crizotinib will be continued till disease progression. Primary end is objective response rate. The secondary endpoints include progression-free survival, overall survival and safety profiles. ;


Study Design


Related Conditions & MeSH terms


NCT number NCT04030429
Study type Interventional
Source National Cheng-Kung University Hospital
Contact Keng-Fu Hsu, PhD
Phone +886-6-2353535
Email d5580@mail.ncku.edu.tw
Status Recruiting
Phase Phase 2
Start date September 1, 2019
Completion date February 2024

See also
  Status Clinical Trial Phase
Recruiting NCT05001282 - A Study to Evaluate ELU001 in Patients With Solid Tumors That Overexpress Folate Receptor Alpha (FRĪ±) Phase 1/Phase 2
Recruiting NCT03621904 - PROMOTE Study: Prediction of Response Of HorMOnal Treatment in Advanced and Recurrent Endometrial Cancer
Recruiting NCT02922764 - A Study of RGX-104 in Patients With Advanced Lung & Endometrial Cancer Phase 1
Active, not recruiting NCT03485729 - ONC201 in Recurrent or Metastatic Type II Endometrial Cancer Endometrial Cancer Phase 2
Recruiting NCT05410717 - CLDN6/GPC3/Mesothelin/AXL-CAR-NK Cell Therapy for Advanced Solid Tumors Phase 1
Completed NCT03015129 - A Study of Durvalumab With or Without Tremelimumab in Endometrial Cancer Phase 2